［2］Remus N, Alcais A, Abel L. Human genetics of common mycobacterial infections［J］. Immunol Res, 2003, 28(2):109-129.
［3］Malik S, Abel L, Tooker H, Poon A, Simkin L, Girard M, et al. Alleles of the NRAMP1 gene are risk factors for pediatric tuberculosis disease［J］. Proc Natl AcadSci USA, 2005, 102（34）:12183-12188.
［4］Capparelli R, Iannaccone M, Palumbo D, Medaglia C, Moscariello E, Russo A, et al. Role played by human mannose-binding lectin polymorphisms in pulmonary tuberculosis［J］. J Infect Dis, 2009, 199(5):666-672.
［5］Sallakci N, Coskun M, Berber Z, Gürkan F, Kocamaz H, Uysal G, et al. Interferongamma gene +874T-A polymorphism is associated with tuberculosis and gamma interferon response［J］. Tuberculosis (Edinb), 2007, 87(3):225-230.
［6］Sánchez D, Rojas M, Hernández I, Radzioch D, García LF, Barrera LF. Role of TLR2-and TLR4-mediated signaling in Mycobacterium tuberculosis-induced macrophage death［J］.Cell Immunol, 2010, 260(2):128-136.
［7］Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphiam in the toll-like receptor 2 gene and its potential association with staphylococcal infection［J］. Infect Immun, 2000, 68(11):6398-6401.
［8］Bochud PY, Hawn TR, Aderem A. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling［J］. J Immunol, 2003, 170(7):3451-3454.
［9］Schroder NW, Hermann C, Hamann L, Gobel UB, Hartung T, Schumann RR. High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele specific PCR［J］. J Mol Med, 2003, 81(6):368-372.
［10］Ogus AC, Yoldas B, Ozdemir T, Uguz A, Olcen S, Keser I, et al. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease［J］. Eur Respir J, 2004, 23(2):219-223.
［11］Ben-Ali M, Barbouche MR, Bousnina S, Chabbou A, Dellagi K. Toll-like receptor 2 Arg677Trp polymorphism is associated with susceptibility to tuberculosis in Tunisian patients［J］. Clin Diagn Lab Immunol, 2004, 11(3):625-626.
［13］Ferwerda B, Kibiki GS, Netea MG, Dolmans WM, van der Ven AJ. The toll-like receptor 4 Asp299Gly variant and tuberculosis susceptibility in HIV-infected patients in Tanzania［J］. AIDS, 2007, 21(10):1375-1377.
［14］Newport MJ, Allen A, Awomoyi AA, Dunstan SJ, McKinney E, Marchant A,et al. The tolllike receptor 4 Asp299Gly variant: no influence on LPS responsiveness or susceptibility to pulmonary tuberculosis in The Gambia［J］. Tuberculosis (Edinb), 2004, 84(6):347-352.
［15］Davila S, Hibberd ML, Hari Dass R, Wong HE, Sahiratmadja E, Bonnard C,et al. Genetic association and expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis［J］. PLoS Genet, 2008, 4(10):e1000218.
［16］Hawn TR, Dunstan SJ, Thwaites GE, Simmons CP, Thuong NT, Lan NT, et al. A polymorphism in tollinterleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis［J］. J Infect Dis, 2006, 194(8):1127-1134.
［17］Ma X, Liu Y, Gowen BB, Graviss EA, Clark AG, Musser JM. Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease［J］. PLoS One, 2007, 2(12):e1318.
［18］Gomez LM, Camargo JF, Castiblanco J, Ruiz-Narváez EA, Cadena J, Anaya JM. Analysis of IL1B, TAP1, TAP2 and IKBL polymorphisms on susceptibility to tuberculosis［J］. Tissue Antigens, 2006, 67(4):290-296.
［19］Madan T, Saxena S, Murthy KJ, Muralidhar K, Sarma PU. Association of polymorphisms in the collagen region of human SP-A1 and SP-A2 genes with pulmonary tuberculosis in Indian population［J］. Clin Chem Lab Med, 2002, 40(10):1002-1008.
［20］Malik S, Greenwood CM, Eguale T, Kifle A, Beyene J, Habte A. Variants of the SFTPA1 and SFTPA2 genes and susceptibility to tuberculosis in Ethiopia［J］.Hum Genet, 2006, 118(6):752-759.
［21］Herb F, Thye T, Niemann S, Browne EN, Chinbuah MA, Gyapong J, et al. ALOX5 variants associated with susceptibility to human pulmonary tuberculosis［J］. Hum Mol Genet, 2008, 17(7):1052-1060.
［22］Boodhoo A, Wong AM, Williamson D, Voon D, Lee S, Allcock RJ, et al. A promoter polymorphism in the central MHC gene, IKBL, influences the binding of transcription factors USF1 and E47 on disease-associated haplotypes［J］. Gene Expr, 2004, 12(1):1-11.
［23］Park GY, Im YH, Ahn CH, Park JW, Jeong SW, Ahn JY, et al. Functional and genetic assessment of IFN-gamma receptor in patients with clinical tuberculosis［J］. Int J Tuberc Lung Dis, 2004, 8(10):1221-1227.
［24］Jamieson SE, Miller EN, Black GF, Peacock CS, Cordell HJ, Howson JM, et al. Evidence for a cluster of genes on chromosome 17q11-q21 controlling susceptibility to tuberculosis and leprosy in Brazilians［J］. Genes Immun, 2004, 5(1): 46-57.
［25］Bellamy R, Beyers N, McAdam KP, Ruwende C, Gie R, Samaai P. Genetic susceptibility to tuberculosis in Africans: a genome-wide scan［J］. Proc Natl Acad Sci USA, 2000, 97(14):8005-8009.
［26］Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J, Kornfeld H. Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth［J］. Infect Immun, 2002, 70(4):1684-1693.
［27］Thuong NT, Dunstan SJ, Chau TT, Thorsson V, Simmons CP, Quyen NT, et al. Identification of tuberculosis susceptibility genes with human macrophage gene expression profiles［J］. PLoS Pathog, 2008, 4(12):e1000229.
［28］Flores-Villanueva PO, RuizMorales JA, Song CH, Flores LM, Jo EK, Montano M, et al. A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis［J］. J Exp Med, 2005, 202(12):1649-1658.
［30］Thye T, Nejentsev S, Intemann CD, Browne EN, Chinbuah MA, Gyapong J,et al. MCP-1 promoter variant-362C associated with protection from pulmonary tuberculosis in Ghana［J］. West Africa.Hum Mol Genet, 2009, 18(2):381-388.
［31］Sánchez-Castanón M, Baquero IC, Sánchez-Velasco P, Farinas MC, Ausín F, Leyva-Cobián F, et al. Polymorphisms in CCL5 promoter are associated with pulmonary tuberculosis in northern Spain［J］. Int J Tuberc Lung Dis, 2009,13(4):480-485.
［32］Chu SF, Tam CM, Wong HS, Kam KM, Lau YL, Chiang AK. Association between RANTES functional polymorphisms and tuberculosis in Hong Kong Chinese［J］. Genes Immun, 2007, 8(6):475-479.
［33］Boutlis CS, Hobbs MR, Marsh RL, Misukonis MA, Tkachuk AN, Lagog M, et al. Inducible nitric oxide synthase (NOS2) promoter CCTTT repeat polymorphism: relationship to in vivo nitric oxide production/NOS activity in an asymptomatic malaria-endemic population［J］. Am J Trop Med Hyg, 2003, 69(6):569-573.
［34］Giovammoni L. TNFA locus is associated with beta degrees 39 thalassemia in Corsica and Sardinia［J］.Eur Cytokine Netw, 2008,19(4):196-203.
［35］Gómez LM, Anaya JM, Vilchez JR, Cadena J, Hinojosa R, Vélez L, et al. A polymorphism in the inducible nitric oxide synthase gene is associated with tuberculosis［J］. Tuberculosis (Edinb), 2007, 87(4):288-294.
［36］Velez DR, Hulme WF, Myers JL, Stryjewski ME, Abbate E, Estevan R, et al. Association of SLC11A1 with tuberculosis and interactions with NOS2A and TLR2 in African-Americans and Caucasians［J］. Int J Tuberc Lung Dis, 2009, 13(9):1068-1076.
［37］Gomez LM, Anaya JM, Martin J. Genetic influence of PTPN22 R620W polymorphism in tuberculosis［J］. Hum Immunol, 2005, 66(12):1242-1247.
［38］Cooke GS, Campbell SJ, Bennett S, Lienhardt C, McAdam KP, Sirugo G, et al. Mapping of a novel susceptibility locus suggests a role for MC3R and CTSZ in human tuberculosis［J］. AM J Respir Crit Care Med, 2008, 78(2):203-207.
［39］Ottenhoff TH, Verreck FA, Hoeve MA, van de Vosse E. Control of human host immunity to mycobacteria［J］. Tuberculosis (Edinb), 2005, 85(1-2):53-64.
［40］Jouanguy E, Lamhamedi-Cherradi S, Lammas D, Dorman SE, Fondanèche MC, Dupuis S, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection［J］. Nat Genet, 1999, 21(4):370-378.
［41］Koscielniak E, de Boer T, Dupuis S, Naumann L, Casanova JL, Ottenhoff TH. Disseminated Mycobacterium peregrinum infection in a child with complete interferon-γ receptor-1 deficiency［J］. Pediatr Infect Dis J, 2003, 22(4):378-380.
［42］Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon-γ receptor and susceptibility to mycobacterial infection［J］. J Clin Invest, 1998,101(11):2364-2369.
［43］Rosenzweig SD, Dorman SE, Uzel G, Shaw S, Scurlock A, Brown MR, et al. A novel mutation in IFN-γ receptor 2 with dominant negative activity:biological consequences of homozygous and heterozygous States［J］. J Immunol, 2004, 173 (6):4000-4008.
［44］Doffinger R, Jouanguy E, Dupuis S, Fondanèche MC, Stephan JL, Emile JF, et al. Partial interferon-γ receptor signaling chain deficiency in a patient with Bacille Calmette-Guérin and Mycobacterium abscessus infection［J］. J Infect Dis, 2000, 181 (1):379-384.
［45］Picard C, Fieschi C, Altare F, Al-Jumaah S, Al-Hajjar S, Feinberg J, et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds［J］. Am J Hum Genet, 2002,70 (2):336-348.
［46］Elloumi-Zghal H, Barbouche MR, Chemli J, Béjaoui M, Harbi A, Snoussi N, et al. Clinical and genetic heterogeneity of inherited autosomal recessive susceptibility to disseminated Mycobacterium bovis Bacille Calmette-Guérin infection［J］. J Infect Dis, 2002,185(10):1468-1475.
［47］Pedraza-Sánchez S, Herrera-Barrios MT, Aldana-Vergara R,Neumann-Ordonez M, González-Hernández Y, Sada-Díaz E, et al. Bacille Calmette-Guérin infection and disease with fatal outcome associated with a point mutation in the interleukin-12/interleukin-23 receptor beta-1 chain in two Mexican families［J］. Int J Infect Dis, 2010 Feb 18. ［Epub ahead of print］.
［48］Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis［J］. Hepatology, 2003, 37(4):924-930.
